News

Cabotegravir is yet to be approved by regulatory authorities anywhere in the world.  It is the first injectable to be studied for efficacy in pre-exposure prophylaxis. Dubbed HPTN 083, the 4,500-subject

This collaboration will grant Taiho access to X-Chem’s DEX technology which is based on DNA-encoded libraries of small molecules with more than 120 billion molecules. The aim of

These products will be packaged and marketed as store brands or retailer 'own label' brands and provide consumers with high-quality, value alternatives to Nicorette White Ice Mint Gum.

The extension is the result of the submission of additional data by Genentech regarding the commercial manufacturing process of OCREVUS, which required additional time for FDA review. The

Under the deal, Bristol-Myers will pay $50m upfront and will be solely responsible for worldwide clinical development and commercialization activities associated to the NG-348 virus. The deal also

The study will investigate the effects of once-daily closed triple combination therapy fluticasone furoate/ umeclidinium/vilanterol compared to therapy with the once-daily dual combination therapy, Relvar/Breo(R) (FF/VI). Comprising three

COMPASS is a randomized, double-blind, placebo-controlled, 26-week Phase 3 study evaluating volanesorsen in 113 patients with severe hypertriglyceridemia. The average incoming triglyceride level of patients in the study

Tresiba, first approved by the FDA in September 2015, is now indicated to improve glycemic control in patients with type 1 and type 2 diabetes from the age

Nimenrix is now the first and only MenACWY conjugate vaccine in the European Union (EU) that can be administered from six weeks of age with no upper age